Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Santiago

Adult Medicine Miami, FL Medical Doctor

NPI 1316080682 CMS profile 59914

3510 Biscayne Blvd, Suite 300, Miami, FL 33137

Open in the dashboard

General payments

$289,608

748 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Santiago of Miami, FL is reported in the CMS Open Payments database as having received $289,608 across 748 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Adult Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,953 53
2024 General $23,039 85
2023 General $41,503 141
2022 General $27,093 74
2021 General $24,198 91
2020 General $33,647 60
2019 General $122,176 244

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Santiago
  • Adult Medicine median
  • Middle half of Adult Medicine
  • National median

In program year 2025, general payments to Steven Santiago were reported at $17,953. Among 691 Adult Medicine profiles paid that year, the median was $151 and the middle half received between $51 and $528.

Show as a table
Year Steven Santiago Adult Medicine median Middle half National median
2019 $122,176 $140 $41–$517 $163
2020 $33,647 $107 $25–$378 $114
2021 $24,198 $136 $32–$529 $132
2022 $27,093 $138 $39–$492 $149
2023 $41,503 $155 $46–$483 $160
2024 $23,039 $153 $46–$554 $164
2025 $17,953 $151 $51–$528 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $134,236 290 payments
  2. Janssen Scientific Affairs, LLC $117,533 183 payments
  3. ViiV Healthcare Company $30,437 154 payments
  4. Theratechnologies Inc. $2,989 30 payments
  5. Janssen Products, LP $2,640 2 payments
  6. Janssen Biotech, Inc. $818 50 payments
  7. Merck Sharp & Dohme Corporation $348 19 payments
  8. EMD Serono, Inc. $323 5 payments
  9. Exact Sciences Corporation $113 6 payments
  10. Pfizer Inc. $63 3 payments
  11. Other $107 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $197,025 119 payments
  2. Travel and Lodging $42,185 126 payments
  3. Consulting Fee $35,530 15 payments
  4. Food and Beverage $14,817 485 payments
  5. Education $50 3 payments
Products named General payments · program years 2019–2025
  1. SYMTUZA $120,991 235 payments
  2. Descovy $57,438 69 payments
  3. Biktarvy $39,632 46 payments
  4. DOVATO $11,544 94 payments
  5. Yeztugo $7,024 8 payments
  6. Truvada $7,000 5 payments
  7. EGRIFTA $989 28 payments
  8. TROGARZO $689 27 payments
  9. DELSTRIGO $348 19 payments
  10. PIFELTRO $313 16 payments
  11. Other $2,020 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

494

Median for Family Practice: 1,826

Drug cost

$980,278

Median for Family Practice: $120,094

Branded share of claims

60.5%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 129 $499,433
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 25 $126,417
Cabenuva Cabotegravir/Rilpivirine Brand 19 $117,523
Dovato Dolutegravir Sodium/Lamivudine Brand 32 $98,191
Juluca Dolutegravir/Rilpivirine Brand 11 $44,047
Tivicay Dolutegravir Sodium Brand 18 $43,904
Mytesi Crofelemer Brand 13 $30,758
Ozempic Semaglutide Brand 16 $16,637
Valacyclovir Valacyclovir Hcl Brand 24 $958
Rosuvastatin Calcium Generic 42 $882

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Descovy
  • Gilead Sciences, Inc. $11,331
$11,331 — —
Biktarvy
  • Gilead Sciences, Inc. $9,690
$9,690 129 —
DOVATO
  • ViiV Healthcare Company $630
$630 32 —
APRETUDE
  • ViiV Healthcare Company $184
$184 — —
EGRIFTA
  • Theratechnologies Inc. $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

748 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record